Background: Myxosarcomas (MXS) are malignant mesenchymal neoplasms originated from mainly mucin producing fibroblasts than collagen. Despite malignant neoplasms, MXS is believed to have low metastase generation ability. Myxosarcomas reports in dogs are widespread, usually involving trunk and limbs subcutaneous tissue. The aim of this report is to describe clinical, pathological, and immunohistochemistry aspects of a rare case of splenic myxosarcoma in a dog. Case: A 10-year-old, intact male Basset Hound, weiging 25 kg, showing signals such apathy, dark soft-stooled stools, progressive thinning, and increasing abdominal enlargement, perceived three months ago was brought to clinical consultation. Physical examination showed extremely pale or...
Non-angiomatous-non-lymphomatous sarcomas (NANLs) represent 23%_34% of canine primary splenic sarcom...
open8noNon-angiomatous-non-lymphomatous sarcomas (NANLs) represent 23%_34% of canine primary splenic...
Nonvascular-nonlymphoid (NVNL) sarcomas represent 23-34% of canine primary splenic sarcomas. Splenic...
Background: Myxosarcomas (MXS) are malignant mesenchymal neoplasms originated from mainly mucin prod...
Background: Myxosarcomas (MXS) are malignant mesenchymal neoplasms originated from mainly mucin prod...
Background: Myxosarcomas (MXS) are malignant mesenchymal neoplasms originated from mainly mucin prod...
Background: Splenic stromal neoplasms are a heterogeneous group of tumors that shares the morphology...
Non-angiomatous-non-lymphomatous sarcomas (NANLs) represent 23%–34% of canine primary splenic sarcom...
Non-angiomatous-non-lymphomatous sarcomas (NANLs) represent 23%–34% of canine primary splenic sarcom...
Background: Myxosarcoma is a malignant mesenchymal tumor that arises from fibroblasts and is charact...
Non-angiomatous-non-lymphomatous sarcomas (NANLs) represent 23%-34% of canine primary splenic sarcom...
Background: Liposarcoma is a malignant neoplasm of lipoblasts with low incidence in dogs, representi...
Myxosarcoma is an unusual neoplasm in the dog, most seen in the skin, and seldom in the heart and in...
Background: The histiocytic sarcoma (HS) complex is a set of malignant neoplasms originating from in...
Non-angiomatous-non-lymphomatous sarcomas (NANLs) represent 23%_34% of canine primary splenic sarcom...
Non-angiomatous-non-lymphomatous sarcomas (NANLs) represent 23%_34% of canine primary splenic sarcom...
open8noNon-angiomatous-non-lymphomatous sarcomas (NANLs) represent 23%_34% of canine primary splenic...
Nonvascular-nonlymphoid (NVNL) sarcomas represent 23-34% of canine primary splenic sarcomas. Splenic...
Background: Myxosarcomas (MXS) are malignant mesenchymal neoplasms originated from mainly mucin prod...
Background: Myxosarcomas (MXS) are malignant mesenchymal neoplasms originated from mainly mucin prod...
Background: Myxosarcomas (MXS) are malignant mesenchymal neoplasms originated from mainly mucin prod...
Background: Splenic stromal neoplasms are a heterogeneous group of tumors that shares the morphology...
Non-angiomatous-non-lymphomatous sarcomas (NANLs) represent 23%–34% of canine primary splenic sarcom...
Non-angiomatous-non-lymphomatous sarcomas (NANLs) represent 23%–34% of canine primary splenic sarcom...
Background: Myxosarcoma is a malignant mesenchymal tumor that arises from fibroblasts and is charact...
Non-angiomatous-non-lymphomatous sarcomas (NANLs) represent 23%-34% of canine primary splenic sarcom...
Background: Liposarcoma is a malignant neoplasm of lipoblasts with low incidence in dogs, representi...
Myxosarcoma is an unusual neoplasm in the dog, most seen in the skin, and seldom in the heart and in...
Background: The histiocytic sarcoma (HS) complex is a set of malignant neoplasms originating from in...
Non-angiomatous-non-lymphomatous sarcomas (NANLs) represent 23%_34% of canine primary splenic sarcom...
Non-angiomatous-non-lymphomatous sarcomas (NANLs) represent 23%_34% of canine primary splenic sarcom...
open8noNon-angiomatous-non-lymphomatous sarcomas (NANLs) represent 23%_34% of canine primary splenic...
Nonvascular-nonlymphoid (NVNL) sarcomas represent 23-34% of canine primary splenic sarcomas. Splenic...